Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Ilava – page 3

209 clinical trials in Ilava, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Ilava at a glance
209
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

209 trials in Ilava

Open in trial search

Dyslipidaemia

Recruiting

Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid
  • Sponsor:A. Menarini International Licensing S.A.

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Obesity+1

Recruiting

A study to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight and type 2 diabetes

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

A study to compare the efficacy and safety of AVT29 and aflibercept in patients with diabetic macular edema

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Alvotech Swiss AG

A study to evaluate the efficacy and safety of orforglipron in patients with peripheral artery disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

A Study of Amivantamab With Carboplatin and Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Study of oral BI 1815368 compared to placebo in patients with diabetic macular edema over 48 weeks of treatment

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:BI 1815368
  • Sponsor:Boehringer Ingelheim International GmbH

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Ilava

What the registry says about research in the country

01 Cardiovascular Diseases

The clinical trial activity in Ilava includes research in cardiovascular diseases, with a focus on improving protection against major heart-related events and related complications. These studies are exploring new ways to reduce risk in people living with established or high-risk heart conditions.

  • Atherosclerotic cardiovascular disease
  • Established cardiovascular disease
  • High cardiovascular risk
  • Hypertension

The goal is to evaluate whether new treatments can better prevent serious outcomes such as heart attack, stroke, heart failure, and cardiovascular death.

02 Nutritional and Metabolic Diseases

Another key area in this research landscape is nutritional and metabolic diseases, especially conditions linked to excess weight and metabolic risk. The trials are looking at therapies that may support weight reduction while also improving broader health outcomes.

  • Obesity
  • Overweight
  • Chronic kidney disease

In Ilava, this work is aimed at understanding whether newer treatments can help lower the burden of obesity-related complications and support kidney health at the same time.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.